|Bid||130.68 x 800|
|Ask||130.85 x 800|
|Day's Range||129.22 - 131.27|
|52 Week Range||117.19 - 178.86|
|Beta (3Y Monthly)||1.55|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||1.56 (1.19%)|
|1y Target Est||N/A|
San Francisco quietly lost the headquarters of Core-Mark Holding Co., which disclosed on an earnings call that it's moving its headquarters to Dallas next year. Will this health care company follow?
will retire next year, capping a 17-year reign in which he helped build one of the country’s largest pharmaceutical wholesalers despite weathering shareholder criticism over his compensation and handling of the opioid crisis. , McKesson’s lead independent director, will take over as chairman of the board, the company said Thursday. “This is the right time to turn the leadership reins over to the next generation and no one is better equipped than Brian to lead McKesson into the future,” Mr. Hammergren said in a written statement.
Despite the tumult that has engulfed its operating environment, we believe McKesson MCK will remain a key healthcare player and be able to produce outsize economic value. Its fiscal second quarter reflected a stabilization of near-term issues as the company reported earnings above consensus and raised the lower end of its full-year earnings per share guidance. After factoring in these latest results, we are reiterating our $210 fair value estimate and wide economic moat rating for the pharmaceutical distributor.
John Hammergren has been the CEO of McKesson Corporation (NYSE:MCK) since 2001. First, this article will compare CEO compensation with compensation at other large companies. After that, we will consider Read More...
McKesson (MCK) delivered earnings and revenue surprises of 9.76% and -0.90%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the San Francisco-based company said it had profit of $2.51. Earnings, adjusted for one-time gains and costs, were $3.60 per share. The results exceeded Wall Street expectations. ...
McKesson (NYSE: MCK ) unveils its next round of earnings this Thursday, Oct. 25. Here is Benzinga's everything-that-matters guide for the Q2 earnings announcement Earnings and Revenue Analysts expect McKesson ...
Long-term potential of the Medical Products industry looks promising at the moment amid certain short-term geopolitical insecurities.
Yahoo Finance's LIVE market coverage and analysis of what you need to watch in the stock market begins each day at 9:00 a.m. ET.
SAN FRANCISCO (AP) — San Francisco has come to be known around the world as a place for aggressive panhandling, open-air drug use and sprawling tent camps, the dirt and despair all the more remarkable for the city's immense wealth.
On October 3, Gilead Sciences (GILD) reported the results from a phase three study evaluating the safety and efficacy of Biktarvy for treating HIV-1 infections in treatment-naive patients. The drug was found to be statistically non-inferior to a regimen of abacavir, dolutegravir, and lamivudine through 96 weeks of therapy.
Change Healthcare LLC, a healthcare technology company majority-owned by U.S. drug wholesaler McKesson Corp, has hired underwriters for an initial public offering that could value it at as much as $12 billion, including debt, people familiar with the matter said on Wednesday. The move comes after McKesson Chief Executive John Hammergren said in January that he intended to take Change Healthcare public. Tapping underwriters shows that McKesson is gearing up for the IPO, which the sources said is expected to take place in the first half of 2019.
Overall, healthcare valuations have slightly risen to a price/fair value of 1.07, up from 0.98 at the end of the second quarter and 1.04 at the start of the year, but the differences in industry valuations continue to suggest drug, biotech, and drug supply chain industries are the most undervalued areas. Innovative new drug launches combined with strong advancements in drug pipelines are supporting a steady growth outlook for the drug and biotech industries. Concerns around U.S. governmental reforms addressing drug pricing appear to be easing on the valuations for drug manufacturers with the majority of reform concerns still surrounding potential changes to the drug supply chain.
Henry Schein (HSIC) generated revenues of $3.33 billion in the second quarter, compared to revenues of $3.06 billion in the second quarter of 2017. For fiscal 2018 and 2019, the company is expected to generate revenues of $13.41 billion and $14.05 billion, respectively, compared with revenues of $12.46 billion in fiscal 2017.
Investors pursuing a solid, dependable stock investment can often be led to McKesson Corporation (NYSE:MCK), a large-cap worth US$26.33b. Market participants who are conscious of risk tend to search forRead More...
Pharmaceutical companies could soon be required to include the list price of medicines in their TV ads. Yahoo Finance’s Alexis Christoforous and Sibile Marcellus discuss the details.